Study Resources

Before participants are fully enrolled in RISE UP, a medical team will assess each person's medical history and health to ensure they're a good fit for the clinical trial. Key inclusion and exclusion criteria are available at clinicaltrials.gov.¹

In phase 2, participants will receive either mitapivat or placebo tablets to take twice a day, every day, for 3 months. For phase 3 participants, this initial period lasts 1 year. Approximately every 2 weeks, participants will be evaluated by a doctor to measure for changes in anemia, changes in pain crises, and overall health and safety. After the initial study period, participants may choose to continue taking mitapivat, or begin taking mitapivat if previously on placebo, for 4 years.¹

Throughout the study, participant names and medical information will be kept completely confidential. Each participant in the study will be assigned a unique identifier. Records and data collected throughout the study will not contain any names or personal identifying information, only the unique identifier.¹

While the range and type of services available to individuals will depend on local and national regulations, Agios is working to support RISE UP participants so that they can attend clinical trial appointments regularly and without worries. These services may include caregivers, childcare, travel and transportation support, stipends, remote nurse visits, and virtual visits. Local investigators can confirm which services are available. More information about support will also be available on specific local enrollment websites.